Welcome to Part 3 of NBCC’s Key Take-Aways from the 2022 American Society of Clinical Oncology (ASCO) annual conference. In […]
“Changes to FDA warnings and labeling should be grounded in rigorous, contemporary evidence—not post-hoc or subgroup re-analyses of older trials. ”
“As a breast cancer survivor, [Visco] turned pain into purpose, changed the landscape of breast cancer advocacy, and has become a powerful symbol of hope for the nation.”
Nicole Levins, communications director
nlevins@stopbreastcancer.org
Welcome to Part 3 of NBCC’s Key Take-Aways from the 2022 American Society of Clinical Oncology (ASCO) annual conference. In […]
The 117th Congress will adjourn for August recess soon. The House will be out from July 29 to September 12 […]
It’s Time to Think About August Recess Advocacy The 117th Congress is preparing to take a long summer break from Washington […]
Since NBCC’s founding in 1991, our mission has been to end breast cancer through the power of action and advocacy. On […]
ASCO 2022 – Key Take-Aways in Breast Cancer. Are We Making Progress? Part 2 As discussed in our June 27 Science […]
Year after year, researchers, oncologists and other health professionals, industry representatives, and patient advocates descend upon Chicago, Illinois (when not […]
